We recently compiled a list of the Jim Cramer Discusses These 10 Stocks & Comments On OpenAI’s Valuation. In this article, we ...

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

LogiPharma is setting a new standard for sustainability in the life sciences supply chain sector by embedding environmentally ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Hassabis previously told the FT his team was working on six drug development programmes with Eli Lilly and Novartis ... the genie can’t be put back in the bottle . . . so we have to try and make sure ...

On the clinical side, we saw GSK shell out just over $1 billion for gastrointestinal cancer specialists IDRx, while Eli Lilly ... d like my chocolate shake. A bottle of water.

Google Deepmind co-founder Demis Hassabis talks to FT editor Roula Khalaf about the real world healthcare applications of AI and how his ground-breaking work on the structure of proteins could acceler ...

Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...

Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...